Cortagen vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & LongevityRecovery & Repair
CortagenGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- Short peptide half-life; gene regulatory effects persist beyond peptide clearance
- ~7 days (estimated, long-acting design)
- Admin Route
- SubQ, IM, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg SC or IM daily
- Under investigation in Phase 1/2 trials
- Frequency
- Once daily
- Once weekly
- Key Benefits
- Cardioprotective — protects cardiac tissue from ischemic damage
- Promotes cardiac regeneration and repair
- Improves vascular endothelium function
- Reduces atherosclerosis progression
- Anti-aging effect on heart muscle cells
- Improves cardiac output and exercise capacity
- Reduces oxidative stress in cardiovascular tissue
- May reduce arrhythmia frequency
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Excellent safety profile
- Mild injection site reactions
- Rare: transient hypotension
- Rare: mild arrhythmia at initiation in cardiac patients
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —